- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Conformation.
Displaying page 1 of 1.
EudraCT Number: 2018-002633-38 | Sponsor Protocol Number: 08781 | Start Date*: 2018-11-19 |
Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust | ||
Full Title: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children. | ||
Medical condition: Metaphyseal chondrodysplasia type Schmid (MCDS) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006970-45 | Sponsor Protocol Number: 2006.420/13 | Start Date*: 2007-11-26 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: EVALUATION DE L’ASSOCIATION RADIOTHERAPIE DE CONFORMATION ET CHEMOEMBOLISATION INTRA-ARTERIELLE HEPATIQUE EN NEOADJUVANT DE LA RESECTION CHIRURGICALE DES CARCINOMES HEPATOCELLULAIRES DE GRANDE TAILLE | |||||||||||||
Medical condition: Hepatocellular carcinoma respectable | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001969-49 | Sponsor Protocol Number: N15TON | Start Date*: 2015-09-03 | |||||||||||
Sponsor Name:NKI-AvL | |||||||||||||
Full Title: Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple-negative breast cancer (TNBC) patients: TONIC-trial | |||||||||||||
Medical condition: Triple negative breast cancer (TNBC) patients with metastatic disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003118-17 | Sponsor Protocol Number: CRAD001HDE13 | Start Date*: 2011-12-29 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A 12 month, multi-center, open-label, randomized, controlled study to evaluate efficacy/safety and evolution of renal function of everolimus in co-exposure with tacrolimus in de novo liver transpla... | |||||||||||||
Medical condition: liver transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002184-42 | Sponsor Protocol Number: TED12689 | Start Date*: 2016-02-19 | ||||||||||||||||
Sponsor Name:Sanofi-aventis | ||||||||||||||||||
Full Title: A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients with Refractory Solid Tumors Including Tumors of the Central Nervous System | ||||||||||||||||||
Medical condition: Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002210-31 | Sponsor Protocol Number: AC-012-EU | Start Date*: 2019-05-31 |
Sponsor Name:Amyloid Center - Biotechnology Research Laboratories Policlinico San Matteo | ||
Full Title: A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy | ||
Medical condition: Light chain (AL) amyloidosis is a protein conformational disease, caused by a small bone marrow plasma cell clone producing light chains (LCs) that undergo conformational changes, aggregate and d... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2023-000169-14 | Sponsor Protocol Number: INES | Start Date*: 2023-05-03 | |||||||||||
Sponsor Name:Fondazione Santobono Pausilipon ONLUS | |||||||||||||
Full Title: Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma | |||||||||||||
Medical condition: Ewing Sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000753-28 | Sponsor Protocol Number: 212494 | Start Date*: 2021-05-11 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals SA | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose and annual revaccination of GSK’s RSVPreF3 OA investigational vaccine in ... | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) FI (Completed) DE (Completed) IT (Completed) SE (Prematurely Ended) HU (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
